Back

2025 PGROD – Making the Diagnosis When It Counts: Recognizing Treatable Leukodystrophies

Objective(s): 1 Explain how pathophysiology informs trial design for the leukodystrophies. 2 Discuss the different gene therapy approaches for the leukodystrophies. 3 Describe biomarkers monitoring and management of leukodystrophy trials.Location: Nationwide Children’s Hospital Conference CenterSpecialties: General PediatricsFaculty Disclosures: Florian Eichler, MD (Consulting Fee-Atlas Venture|Consulting Fee-ASPA Therapeutucs|Consulting Fee-Acadia|Consulting Fee-Leal Therapeutics|Consulting Fee-Orchard Therapeutics|Consulting Fee-Sanofi Therapeutics|Consulting Fee-Spoila Therapeutics|Consulting Fee-Spur Therapeutics|Consulting Fee-Takeda Therapeutics|Consulting Fee-Up to Date|Grant or research support-GLIA CTN|Grant or research support-European Leukodystrophy Associateion|Ownership-Swan Bio – 03/21/2025)Download Handout

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1 creditAAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 creditSocial WorkUp to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 1 credit
  • Released
    Mar 27, 2025
  • Last day to claim credit
    Mar 28, 2028 1 year left